Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10983284rdf:typepubmed:Citationlld:pubmed
pubmed-article:10983284lifeskim:mentionsumls-concept:C0000968lld:lifeskim
pubmed-article:10983284lifeskim:mentionsumls-concept:C0002771lld:lifeskim
pubmed-article:10983284lifeskim:mentionsumls-concept:C0003209lld:lifeskim
pubmed-article:10983284lifeskim:mentionsumls-concept:C0441655lld:lifeskim
pubmed-article:10983284lifeskim:mentionsumls-concept:C1515999lld:lifeskim
pubmed-article:10983284lifeskim:mentionsumls-concept:C1553027lld:lifeskim
pubmed-article:10983284pubmed:issue5lld:pubmed
pubmed-article:10983284pubmed:dateCreated2000-12-11lld:pubmed
pubmed-article:10983284pubmed:abstractTextA series of substituted 3-(arylamino)-4,5-dihydro-2H-benz[g]indazol-2-yl acetamides was synthesized and tested in comparison with former analogues. The title compounds showed only weak antiarrhythmic properties but good anti-inflammatory and antinociceptive activity, particularly evident in the morpholino derivative.lld:pubmed
pubmed-article:10983284pubmed:languageenglld:pubmed
pubmed-article:10983284pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10983284pubmed:citationSubsetIMlld:pubmed
pubmed-article:10983284pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10983284pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10983284pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10983284pubmed:statusMEDLINElld:pubmed
pubmed-article:10983284pubmed:monthMaylld:pubmed
pubmed-article:10983284pubmed:issn0014-827Xlld:pubmed
pubmed-article:10983284pubmed:authorpubmed-author:BondavalliFFlld:pubmed
pubmed-article:10983284pubmed:authorpubmed-author:FalconeGGlld:pubmed
pubmed-article:10983284pubmed:authorpubmed-author:RaniseAAlld:pubmed
pubmed-article:10983284pubmed:authorpubmed-author:SchenoneSSlld:pubmed
pubmed-article:10983284pubmed:authorpubmed-author:BrunoOOlld:pubmed
pubmed-article:10983284pubmed:authorpubmed-author:FilippelliWWlld:pubmed
pubmed-article:10983284pubmed:authorpubmed-author:RivaldiBBlld:pubmed
pubmed-article:10983284pubmed:issnTypePrintlld:pubmed
pubmed-article:10983284pubmed:volume55lld:pubmed
pubmed-article:10983284pubmed:ownerNLMlld:pubmed
pubmed-article:10983284pubmed:authorsCompleteYlld:pubmed
pubmed-article:10983284pubmed:pagination383-8lld:pubmed
pubmed-article:10983284pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:10983284pubmed:meshHeadingpubmed-meshheading:10983284...lld:pubmed
pubmed-article:10983284pubmed:meshHeadingpubmed-meshheading:10983284...lld:pubmed
pubmed-article:10983284pubmed:meshHeadingpubmed-meshheading:10983284...lld:pubmed
pubmed-article:10983284pubmed:meshHeadingpubmed-meshheading:10983284...lld:pubmed
pubmed-article:10983284pubmed:meshHeadingpubmed-meshheading:10983284...lld:pubmed
pubmed-article:10983284pubmed:meshHeadingpubmed-meshheading:10983284...lld:pubmed
pubmed-article:10983284pubmed:meshHeadingpubmed-meshheading:10983284...lld:pubmed
pubmed-article:10983284pubmed:year2000lld:pubmed
pubmed-article:10983284pubmed:articleTitleN-substituted 3-(arylamino)-4,5-dihydro-2H-benz[g]indazol-2-yl acetamides with anti-inflammatory and analgesic activities.lld:pubmed
pubmed-article:10983284pubmed:affiliationDipartimento di Scienze Farmaceutiche dell'Università di Genova, Italy. bondabsr@unige.itlld:pubmed
pubmed-article:10983284pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:10983284pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed